Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036556 · ClinicalTrials.gov registry record · Phase 3
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 941
- Enrollment target
NCT00036556 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 941 participants.
The verdict
NCT00036556, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 941 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2001-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036556
The ClinicalTrials.gov registry entry for NCT00036556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 941 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT00036556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036556 about?
NCT00036556 is a clinical study titled "Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer". This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
What is the current status of trial NCT00036556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 941 participants. The study started on 2001-06.
What interventions are being tested in trial NCT00036556?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT00036556?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.